Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modulating membrane binding of α-synuclein as a therapeutic strategy.

Literature DB >> 28126719

Modulating membrane binding of α-synuclein as a therapeutic strategy.

André Pineda¹, Jacqueline Burré².

Abstract

Entities: Gene

Mesh：

Substances：
alpha-Synuclein

Year: 2017 PMID： 28126719 PMCID： PMC5307480 DOI： 10.1073/pnas.1620159114

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

× No keyword cloud information.

25 in total

1. Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential.

Authors: Michael Zasloff; A Paige Adams; Bernard Beckerman; Ann Campbell; Ziying Han; Erik Luijten; Isaura Meza; Justin Julander; Abhijit Mishra; Wei Qu; John M Taylor; Scott C Weaver; Gerard C L Wong
Journal: Proc Natl Acad Sci U S A Date: 2011-09-19 Impact factor: 11.205

2. A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity.

Authors: Michele Perni; Céline Galvagnion; Alexander Maltsev; Georg Meisl; Martin B D Müller; Pavan K Challa; Julius B Kirkegaard; Patrick Flagmeier; Samuel I A Cohen; Roberta Cascella; Serene W Chen; Ryan Limbocker; Pietro Sormanni; Gabriella T Heller; Francesco A Aprile; Nunilo Cremades; Cristina Cecchi; Fabrizio Chiti; Ellen A A Nollen; Tuomas P J Knowles; Michele Vendruscolo; Adriaan Bax; Michael Zasloff; Christopher M Dobson
Journal: Proc Natl Acad Sci U S A Date: 2017-01-17 Impact factor: 11.205

Review 3. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

Authors: Benjamin Dehay; Mathieu Bourdenx; Philippe Gorry; Serge Przedborski; Miquel Vila; Stephane Hunot; Andrew Singleton; C Warren Olanow; Kalpana M Merchant; Erwan Bezard; Gregory A Petsko; Wassilios G Meissner
Journal: Lancet Neurol Date: 2015-06-03 Impact factor: 44.182

4. Lipid binding inhibits alpha-synuclein fibril formation.

Authors: Min Zhu; Anthony L Fink
Journal: J Biol Chem Date: 2003-03-05 Impact factor: 5.157

5. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form.

Authors: He-Jin Lee; Chan Choi; Seung-Jae Lee
Journal: J Biol Chem Date: 2001-10-25 Impact factor: 5.157

6. Spin-label EPR on alpha-synuclein reveals differences in the membrane binding affinity of the two antiparallel helices.

Authors: Malte Drescher; Frans Godschalk; Gertjan Veldhuis; Bart D van Rooijen; Vinod Subramaniam; Martina Huber
Journal: Chembiochem Date: 2008-10-13 Impact factor: 3.164

7. α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation.

Authors: Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal: Proc Natl Acad Sci U S A Date: 2014-09-22 Impact factor: 11.205

8. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors: Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal: Science Date: 2010-08-26 Impact factor: 47.728

Review 9. Alpha-synuclein function and dysfunction on cellular membranes.

Authors: David Snead; David Eliezer
Journal: Exp Neurobiol Date: 2014-12-12 Impact factor: 3.261

Review 10. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.

Authors: Matthew J Benskey; Ruth G Perez; Fredric P Manfredsson
Journal: J Neurochem Date: 2016-03-23 Impact factor: 5.372

14 in total

Review 1. Mitochondrial dysfunction in protein conformational disorders.

Authors: Shlomi Brielle; Daniel Kaganovich
Journal: J Genet Date: 2018-07 Impact factor: 1.166

Review 2. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.

Authors: Chao Peng; Ronald J Gathagan; Virginia M-Y Lee
Journal: Neurobiol Dis Date: 2017-07-24 Impact factor: 5.996

3. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis.

Authors: Shobini Jayaraman; Donald L Gantz; Christian Haupt; Olga Gursky
Journal: Proc Natl Acad Sci U S A Date: 2017-07-25 Impact factor: 11.205

Review 4. Postmortem Studies of Fetal Grafts in Parkinson's Disease: What Lessons Have We Learned?

Authors: Jia-Yi Li; Wen Li
Journal: Front Cell Dev Biol Date: 2021-05-13

Review 5. α-Synuclein: An All-Inclusive Trip Around its Structure, Influencing Factors and Applied Techniques.

Authors: Nicolò Bisi; Lucia Feni; Kaliroi Peqini; Helena Pérez-Peña; Sandrine Ongeri; Stefano Pieraccini; Sara Pellegrino
Journal: Front Chem Date: 2021-07-07 Impact factor: 5.221

6. Foldamers reveal and validate therapeutic targets associated with toxic α-synuclein self-assembly.

Authors: Jemil Ahmed; Tessa C Fitch; Courtney M Donnelly; Johnson A Joseph; Tyler D Ball; Mikaela M Bassil; Ahyun Son; Chen Zhang; Aurélie Ledreux; Scott Horowitz; Yan Qin; Daniel Paredes; Sunil Kumar
Journal: Nat Commun Date: 2022-04-27 Impact factor: 17.694

Review 7. Rationally Designed Variants of α-Synuclein Illuminate Its in vivo Structural Properties in Health and Disease.

Authors: Ulf Dettmer
Journal: Front Neurosci Date: 2018-09-25 Impact factor: 4.677